C
Compugen Ltd. (CGEN)
NCM – Real vaqt narxi. Valyuta: USD
2.04
-0.02 (-0.97%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.06
+0.02 (0.98%)
Bozordan keyin: Mar 27, 2026, 6:38 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NCM – Real vaqt narxi. Valyuta: USD
2.04
-0.02 (-0.97%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
2.06
+0.02 (0.98%)
Bozordan keyin: Mar 27, 2026, 6:38 PM EDT
Compugen Ltd., klinik bosqichdagi terapevtik kashfiyot va rivojlantirish kompaniyasi, Isroil, Qo'shma Shtatlar va Yevropada terapevtik vositalar va mahsulot nomzodlarini tadqiq qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning portfelida COM701, anti-PVRIG antitelali immuno-onkologiya portfel dasturi; COM902, terapevtik anti-TIGIT antitelasi, 1-bosqich klinik sinovlarda va qattiq o'smalarni davolash uchun monoterapiya va PVRIG/PD-1 va PVRIG/TIGIT kombinatsiyasida, shuningdek PVRIG/PD-1/TIGIT blokadasi uchun baholangan; Bapotulimab, ILDR2'ni maqsad qilib olgan terapevtik antitelasi, 1-bosqich klinik sinovlarda yangi boshlang'ich bosh va bo'yin yassi hujayrali karsinomasi bo'lgan bemorlarda baholanmoqda; va Rilvegostomig, yangi anti-PD-1/TIGIT bispesifik antitelasi, rivojlangan yoki metastatik mayda hujayrali o'pka saratoni bo'lgan bemorlarda 3-bosqich klinik tadqiqotda. Uning preklinik terapevtik portfeliga immunitetga qarshilikning turli mexanizmlarini hal qilishga qaratilgan dastlabki bosqichdagi immuno-onkologiya dasturlari; va IL-18 bog'lovchi protein va IL-18 o'rtasidagi o'zaro ta'sirni blokirovka qiluvchi yuqori affinlikdagi antitelasi COM503 kiradi. Kompaniya Bristol-Myers Squibb bilan rivojlangan qattiq o'smalari bo'lgan bemorlarda COM701ni Bristol-Myers Squibbning PD-1 immunitet nazorat nuqtasi ingibitori Opdivo bilan birgalikda xavfsizligi va bardoshliligini baholash bo'yicha hamkorlik shartnomasiga ega. U AstraZeneca bilan bispesifik va multispesifik immuno-onkologiya antitel mahsulotlarini ishlab chiqish uchun; va Gilead Sciences, Inc. bilan COM503 va boshqa mahsulotlarni tadqiq qilish, ishlab chiqish, ishlab chiqarish va tijoratlashtirish uchun litsenziyalash shartnomasiga ega. Kompaniya 1993 yilda ro'yxatga olingan va Isroilning Xolon shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Anat Cohen-Dayag Ph.D. | Executive Chair |
| Dr. Eran Ophir Ph.D. | CEO, President & Director |
| Dr. Pierre Ferre Ph.D. | Chief Operating Officer |
| Dr. Sharon Kredo-Russo | Senior Vice President of Research & Discovery |
| Dr. Zurit Levine Ph.D. | Senior Vice President of Business Development |
| Mr. David Silberman CPA | Chief Financial Officer |
| Mr. Eran Ben Dor | General Counsel & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-02 | 6-K | zk2634467.htm |
| 2025-12-17 | 6-K | zk2534122.htm |
| 2025-11-10 | 6-K | zk2533961.htm |
| 2025-10-14 | 6-K | zk2533844.htm |
| 2025-09-17 | 6-K | zk2533793.htm |
| 2025-08-06 | 6-K | zk2533502.htm |
| 2025-07-21 | 6-K | zk2533465.htm |
| 2025-05-19 | 6-K | zk2533219.htm |
| 2025-03-04 | 20-F | zk2532769.htm |
| 2025-01-08 | 6-K | zk2532530.htm |
| Ms. Dorit Amitay |
| Vice President of Human Resources |
| Ms. Michelle Mahler M.D. | Chief Medical Officer |
| Rivka Schwartz | Vice President Research and Discovery |